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Abstract
Background: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder accompanied with an
increased risk of developing type 2 diabetes mellitus and cardiovascular disease; despite being a common
condition, the pathogenesis of PCOS remains unclear. Our aim was to investigate the potential metabolic profiles
for different phenotypes of PCOS, as well as for the early prognosis of complications.
Methods: A total of 217 women with PCOS and 48 healthy women as normal controls were studied. Plasma
samples of subjects were tested using two different analytical platforms of metabolomics: 1H nuclear magnetic
resonance (NMR) and gas chromatography/time-of-flight mass spectrometry (GC/TOF-MS).
Results: Our results showed that carbohydrate, lipid and amino acid metabolisms were influenced in PCOS. The levels of
lactate, long-chain fatty acids, triglyceride and very low-density lipoprotein were elevated, while glucose,
phosphatidylcholine and high-density lipoprotein (HDL) concentrations were reduced in PCOS patients as compared with
controls. Additionally, the levels of alanine, valine, serine, threonine, ornithine, phenylalanine, tyrosine and tryptophan
were generally increased, whereas the levels of glycine and proline were significantly reduced in PCOS samples compared
to controls. Furthermore, the ratio of branched-chain amino acid to aromatic amino acid concentrations (BCAA/AAA) in
PCOS plasma was significantly reduced in PCOS patients and was insusceptible to obesity and insulin sensitivity.
Conclusions: Our results suggested that the enhanced glycolysis and inhibited tricarboxylic acid cycle (TAC) in
women with PCOS. Decrease of BCAA/AAA ratio was directly correlated with the development of PCOS. Ovulatory
dysfunction of PCOS patients was associated with raised production of serine, threonine, phenylalanine, tyrosine
and ornithine. Elevated levels of valine and leucine, and decreased concentrations of glycine in PCOS plasma could
contribute to insulin sensitivity and could be considered as the potential biomarkers for long-term risk assessment
of diabetes mellitus.
Keywords: polycystic ovary syndrome, amino acid metabolism, carbohydrate and lipid metabolism, insulin resis-
tance, inflammation
Background
Polycystic ovary syndrome (PCOS) is a complex and het-
erogeneous endocrine disorder with well established
metabolic abnormalities. The prevalence of PCOS is
approximately 5% to 10% in reproductive-age women [1].
Hyperandrogenism, oligomenorrhea, chronic anovula-
tion, and hyperinsulinemia are common clinical manifes-
tations of PCOS [2]. Women with this syndrome have an
increased risk of developing type 2 diabetes mellitus
(DM2) and cardiovascular disease (CVD) [1,3,4]. The
pathogenesis of PCOS remains a mystery, although it is
considered as a polygenic trait that might result from the
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At present, alterations in several metabolic pathways
have been implicated in the pathophysiology of PCOS,
including abnormalities in steroid hormone regulation
and insulin signaling pathway [7-9]. Moreover, there is
increasing focus on the complications associated with
metabolic disturbances among women with PCOS. Obe-
sity, insulin resistance, dyslipidemia and inflammation
have been recognized as risk factors for developing
DM2 and CVD in PCOS [10,11]. This highlights the
need to understand the metabolic dysfunction in PCOS
for prevention of long-term complications through
appropriate screening, diagnosis and intervention.
In addition, the diagnosis of PCOS has also been a con-
troversial issue [12]. Following the 2003 Rotterdam criteria
[13], PCOS can be divided into four different phenotypes:
(A) hyperandrogenism, chronic anovulation and polycystic
ovaries (HA+AO+PCO); (B) chronic anovulation and
polycystic ovaries but no clinical or biochemical hyperan-
drogenism (AO+PCO); (C) hyperandrogenism and chronic
anovulation but normal ovaries (HA+AO); (D) hyperan-
drogenism and polycystic ovaries but ovulatory cycles
(HA+PCO). However, it is not clear whether routine char-
acteristics of metabolic abnormality markers could be
found in all these phenotypes.
The systemic changes that occur in PCOS reflect not
only changes in ovarian function, but also changes in
whole-body metabolism. Metabolomics enables the char-
acterization of endogenous small molecules that serve as
direct profiles of biochemical activity and correlate with
the phenotype [14]. As compared with genomics, tran-
scriptomics and proteomics, metabolomics provides the
most predictive biomarkers of this disease. In order to
investigate potential metabolic profiles for different pheno-
types of PCOS, as well as for the early prognosis of com-
plications, we conducted a plasma metabolomic analysis
to investigate the metabolic changes underlying different
phenotypes of PCOS using both 1H nuclear magnetic
resonance (NMR) and gas chromatography/time-of-flight
mass spectrometry (GC/TOF-MS); these demonstrated to
be complementary analytical technologies [15].
Methods
Study populations
This randomized study population consisted of 217
PCOS patients and 48 women of similar age as controls,
who visited the Division of Reproductive Center, Peking
University Third Hospital, from March 2010 to March
2011. According to 2003 Rotterdam criteria, the diagnos-
tic traits of PCOS are the presence of two or more of:
oligo-ovulation and/or anovulation, clinical and/or bio-
chemical signs of hyperandrogenism, and polycystic ovar-
ies after exclusion of other etiologies (congenital adrenal
hyperplasia, androgen-secreting tumors, Cushing’s syn-
drome, 21-hydroxylase-deficient non-classic adrenal
hyperplasia, androgenic/anabolic drug use or abuse,
thyroid dysfunction, hyperprolactinemia, type 2 diabetes
mellitus and cardiovascular disease). Women who had
received any hormonal treatment or insulin-lowering
agent during the last 3 months were excluded from the
study. The control subjects were selected from women
attending the clinic on account of male azoospermia.
All controls had regular menstrual cycles and normal
androgen levels. This study was approved by the Ethics
Committee of Peking University Third Hospital.
Informed consent was obtained from all participants
prior to inclusion in this study.
Sample preparation and metabolomic assays
Venous blood (3 ml) was collected into a heparin sodium
tube and the plasma was collected by centrifugation.
Each plasma sample was split into two aliquots and run
in parallel using two different analytical platforms, as
described previously [16,17].
For the 1H NMR measurement, an aliquot of 300 μl of
plasma was mixed with 250 μl D2O and 50 μl 3-tri-
methylsilyl-2H4-propionic acid sodium salt (TSP) in D2O
(1 mg/ml) in a 5 mm NMR tube. The D2O provided a
field-frequency lock solvent for the NMR spectrometer
and the TSP served as an internal reference of chemical
shift. 1H NMR spectra of the plasma samples were
acquired on a Varian INOVA 600 MHz NMR spectro-
meter at 27 °C by using Carr-Purcell-Meiboom-Gill
(CPMG) spin-echo pulse sequence with a total spin-spin
relaxation delay (2nτ) of 320 ms. The free induction
decays (FIDs) were collected into 32K data points with a
spectral width of 8,000 Hz and 64 scans. The FIDs were
zero-filled to double size and multiplied by an exponen-
tial line-broadening factor of 0.5 Hz prior to Fourier
transformation (FT). In addition, diffusion-edited experi-
ments were also carried out with bipolar pulse pair-longi-
tudinal eddy current delay (BPP-LED) pulse sequence.
The gradient amplitude was set at 35.0 G/cm, with a dif-
fusion delay of 100 ms. A total of 128 transients and 16K
data points were collected with a spectral width of 8,000
Hz. A line-broadening factor of 1 Hz was applied to FIDs
before Fourier transformation. All plasma 1H NMR spec-
tra were manually phased and baseline-corrected using
VNMR 6.1C software (Varian, Inc.). For CPMG spectra,
each spectrum over the range of δ 0.4 to 4.4 was
data reduced into integrated regions of equal width
(0.01 ppm). For BPP-LED data, each spectrum over the
range of δ 0.1 to 6.0 was segmented into regions of equal
width (0.01 ppm). The regions containing the resonance
from residual water (δ 4.6 to 5.1) were excluded. The inte-
gral values of each spectrum were normalized to a con-
stant sum of all integrals in a spectrum in order to reduce
any significant concentration differences between samples.
Identification of metabolites in spectra was accomplished
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based on information in the literature and the Chenomx
NMR Suite 5.0 (Chenomx, Calgary, Canada).
For the GC/TOF-MS measurement, plasma samples
(100 μl) were thawed before the immediate addition of
500 μl of methanol (100%) to stop enzymatic activity. The
samples were vortexed thoroughly, and 20 μl of a ribitol
stock solution (0.2 mg/ml) was added as an internal refer-
ence. The mixture was placed on a shaker at 70°C for
15 minutes and centrifuged at 10,000 g for 10 minutes.
The supernatant was mixed with 500 μl of pure water and
250 μl of chloroform, and was centrifuged at 4,000 rpm
for 15 minutes. The upper (polar) phase was separated
and then evaporated to dryness under a stream of N2 gas
in a thermostatically controlled water bath (60°C). Meth-
oxyamine hydrochloride (20 μl, 20 mg/ml pyridine) was
then added to the dried fraction of the polar phase. Fol-
lowing continuous shaking at 30°C for 90 minutes, 40 μl
of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA)
was added, and the tube was incubated at 37°C for 30 min-
utes, then kept at room temperature for 120 minutes.
Solutions (0.3 μl) were injected at a split ratio of 25:1 into
a GC/TOF-MS system consisting of an HP 6890 gas chro-
matograph and a time-of-flight mass spectrometer
(Waters Co., Milford, MA, USA) on a 30 m DB-5 column
(250 μm inner diameter., 0.25 μm film; Agilent Technolo-
gies, Palo Alto, CA, USA). The injection temperature was
230°C, the interface temperature was set to 290°C, and the
ion source temperature was adjusted to 220°C, with elec-
tron energy of 70 eV. Helium was set to a column flow
rate of 1 ml/min. After a 5-minute solvent delay time at
70°C, the oven temperature was increased to 310°C in
increments of 5°C/min, followed by a 1-minute isocratic
cool down to 70°C and an additional 5-minute delay.
MassLynx software (Waters Co.) was used to acquire the
chromatographs. NIST02 libraries with electron impact
(EI) spectra were searched rigorously for all the peaks
detected with the total ion current (TIC), to identify the
metabolites. Compounds were also identified by compari-
son of their mass spectra and retention times with those
of commercially available reference compounds. The inte-
gral values of each spectrum were normalized to the inte-
gral of ribitol stock in order to reduce any significant
concentration differences between samples.
Data analysis
Multivariate pattern recognition analysis was carried out
by using SIMCA-P plus software (V. 10.0). Principal
component analysis (PCA) was performed for data from
different groups to detect the distributions and separa-
tions among those groups. Prior to PCA, all data vari-
ables were mean centered and preprocessed using
orthogonal signal correction (OSC) to remove variations
from non-correlated factors such as the instability of the
spectrometer, inconstancy in sample preparation, and
variability of some metabolites depending on the subject.
Multiple comparisons of the measured metabolite inten-
sities of PCOS subgroups and the control group were
made by one-way analysis of variance (ANOVA) analysis
using SPSS V. 19 (SPSS, Chicago, IL, USA), and the
adjustment methods was the Bonferroni correction. Values
were presented as mean ± SD, and an adjusted P value
<0.05 was considered statistically significant. Associations
between the specific metabolites and PCOS controlling for
age, body mass index (BMI) and insulin resistance (IR)
were tested by linear regression analysis (SPSS V. 19).
Results
Baseline characteristics
Of 217 PCOS patients according to the Rotterdam guide-
lines, they were 72 patients (33.2%) presented with the
classic PCOS phenotype (HA+AO+PCO); 74 patients
(34.1%) with chronic anovulation and polycystic ovaries
but no clinical or biochemical hyperandrogenism
(AO+PCO); 33 patients (15.2%) with hyperandrogenism
and chronic anovulation but normal ovaries (HA+AO); 38
patients (17.5%) with hyperandrogenism and polycystic
ovaries but ovulatory cycles (HA+PCO). Baseline charac-
teristics for patients with different phenotypes of PCOS
and controls were described in Table 1. A broad spectrum
of metabolic and biochemical changes in PCOS subgroups
compared with the control group were indicated, includ-
ing the obviously enhanced triglyceride and low-density
lipoprotein (LDL) level and reduced HDL level, a marked
augment in serum concentrations of androgens such as
androstenedione, increased ratio of luteinizing hormone
(LH) to follicle-stimulating hormone (FSH). Overall, these
changes in PCOS patients were clinically associated with
the phenotypes and complemented the metabolomic
analysis.
Aberrance of carbohydrate and lipid metabolism in PCOS
The plasma samples from the PCOS and control groups
were analyzed using 1H NMR spectroscopy. OSC-PCA
was performed to evaluate the population structure of
each PCOS subgroup comparing to the control group
(Figure 1). The metabolites responsible for the differences
among the various groups were identified and summarized
in Table 2. The results showed that all of the four PCOS
phenotypes had higher levels of very low-density lipopro-
tein (VLDL), LDL, fatty acids, unsaturated fatty acids and
an unidentified sugar (δ 3.74 ppm), but had lower levels of
phosphatidylcholine and lysyl-albumin as compared with
the control group, respectively, which indicated the aber-
rance of lipid metabolism in PCOS. Specially, elevated
level of lactate and reduced level of glucose in PCOS
phenotypes except the feature (HA+AO) showed the
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Table 1 Baseline characteristics of four polycystic ovary syndrome (PCOS) phenotypes and control subjects
Characteristic PCOS Controls
A (HA+AO+PCO) C (HA+AO) D (HA+PCO)
Number 72 (33.2%) 74 (34.1%) 33 (15.2%) 38 (17.5%) 48
Age, years 28.00 ± 0.59 28.74 ± 0.45 28.03 ± 0.65 28.79 ± 0.53 29.78 ± 0.56
BMI, kg/m2 24.29 ± 0.46** 24.57 ± 0.54** 25.37 ± 0.81** 24.21 ± 0.67** 21.63 ± 0.36
LH, mIU/ml 11.58 ± 0.77** 7.57 ± 1.04** 6.47 ± 0.95** 7.10 ± 1.28** 3.95 ± 0.26
LH/FSH 1.74 ± 0.10** 1.18 ± 0.17** 1.09 ± 0.12** 1.10 ± 0.14** 0.54 ± 0.03
T, nmol/l 2.06 ± 0.09** 1.26 ± 0.06* 1.73 ± 0.13** 1.95 ± 0.16** 1.31 ± 0.10
A, nmol/l 16.07 ± 0.50** 7.98 ± 0.25* 14.32 ± 0.78** 17.18 ± 1.05** 6.55 ± 0.27
CHO, mmol/l 4.84 ± 0.09* 4.66 ± 0.10 4.85 ± 0.18 5.23 ± 0.18** 4.42 ± 1.32
TG, mmol/l 1.47 ± 0.09** 1.44 ± 0.10* 1.50 ± 0.17* 1.56 ± 0.12* 1.04 ± 0.13
HDL, mmol/l 1.23 ± 0.03** 1.17 ± 0.03** 1.20 ± 0.05* 1.29 ± 0.05 1.38 ± 0.04
LDL, mmol/l 2.93 ± 0.08** 2.88 ± 0.10* 3.03 ± 0.17* 3.13 ± 0.16** 2.47 ± 0.13
Data are presented as mean ± SD. *P <0.01; **P <0.001. A = androstenedione; AO = anovulation; BMI = body mass index; CHO = cholesterol; FSH = follicle-
stimulating hormone; HA = hyperandrogenism; HDL = high-density lipoprotein; LDL = low-density lipoprotein; LH = luteinizing hormone; PCO = polycystic
ovaries; TG = triglyceride.
Figure 1 1H nuclear magnetic resonance (NMR) analysis. Orthogonal signal correction/principal component analysis (OSC-PCA) scores plot (left
column) and loadings plots (right column) for Carr-Purcell-Meiboom-Gill (CPMG) 1H-NMR spectra of plasma from the four phenotypes of polycystic
ovary syndrome (PCOS) patients (red squares) and controls (black triangles). (A) PCOS patients with hyperandrogenism (HA), anovulation (AO) and
polycystic ovaries (PCO) (HA+AO+PCO) vs controls; (B) PCOS patients with anovulation and polycystic ovaries (AO+PCO) vs controls; (C) PCOS patients
with hyperandrogenism and anovulation (HA+AO) vs controls; (D) PCOS patients with hyperandrogenism and polycystic ovaries (HA+PCO) vs controls.
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Table 2 Changes in the relative levels of metabolites in polycystic ovary syndrome (PCOS) phenotypes compared with the control group based on the Carr-
Purcell-Meiboom-Gill (CPMG) and bipolar pulse pair-longitudinal eddy current delay (BPP-LED) 1H nuclear magnetic resonance (NMR) spectra
Chemical shift, ppm Identified metabolites Control group A group (HA+AO+PCO) B group (AO+PCO) C group (AO+HA) D group (HA+PCO)
Mean ± SD P adjusted Mean ± SD P adjusted Mean ± SD P adjusted Mean ± SD P adjusted
CPMG
0.84 to 0.90, 1.26 to 1.30 Lipoprotein 0.09 ± 0.003 0.12 ± 0.005 <0.001 U 0.10 ± 0.005 0.044 U 0.12 ± 0.005 0.005 U 0.13 ± 0.005 <0.001 U
1.31 to 1.34, 4.09 to 4.14 Lactate 0.13 ± 0.004 0.15 ± 0.003 0.006 U 0.15 ± 0.004 0.006 U 0.14 ± 0.005 1.000 - 0.16 ± 0.005 0.001 U
1.46 to 1.48 Alanine 0.018 ± 0.004 0.019 ± 0.003 1.000 - 0.018 ± 0.004 1.000 - 0.019 ± 0.004 1.000 - 0.019 ± 0.004 1.000 -
3.40 to 4.00 Glucose 0.44 ± 0.05 0.40 ± 0.05 0.001 D 0.41 ± 0.05 0.013 D 0.42 ± 0.06 1.000 - 0.39 ± 0.06 0.001 D
3.74 U 0.009 ± 0.002 0.013 ± 0.002 <0.001 U 0.013 ± 0.002 <0.001 U 0.012 ± 0.003 <0.001 U 0.013 ± 0.002 <0.001 U
BPP-LED
0.9,0.86, 1.26,1.3,1.34 VLDL/LDL 0.25 ± 0.04 0.28 ± 0.05 0.009 U 0.27 ± 0.05 0.045 U 0.27 ± 0.06 0.032 U 0.29 ± 0.05 0.008 U
1.22 HDL 0.051 ± 0.005 0.048 ± 0.006 0.025 D 0.050 ± 0.007 1.000 - 0.050 ± 0.006 1.000 - 0.047 ± 0.007 0.047 D
1.58 Lipid- CH2CH2CO 0.012 ± 0.003 0.014 ± 0.003 0.018 U 0.013 ± 0.003 0.453 - 0.014 ± 0.005 0.276 - 0.014 ± 0.004 0.005 U
2.06 NAc 0.018 ± 0.001 0.018 ± 0.001 1.000 - 0.017 ± 0.002 0.105 - 0.017 ± 0.001 0.012 D 0.017 ± 0.001 0.001 D
2.22 FA 0.59 ± 0.96 0.72 ± 0.17 <0.001 U 0.73 ± 0.19 <0.001 U 0.80 ± 0.22 <0.001 U 0.82 ± 0.18 <0.001 U
2.02, 2.74, 5.18 to 5.3 UFA 0.071 ± 0.005 0.078 ± 0.007 <0.001 U 0.077 ± 0.008 <0.001 U 0.076 ± 0.009 0.049 U 0.077 ± 0.007 0.001 U
2.94 to 2.98 Lysyl-albumin 0.014 ± 0.002 0.011 ± 0.002 <0.001 D 0.012 ± 0.002 <0.001 D 0.012 ± 0.003 0.024 D 0.011 ± 0.002 <0.001 D
3.22, 3.26 PtdCho 0.027 ± 0.005 0.023 ± 0.005 <0.001 D 0.023 ± 0.005 <0.001 D 0.022 ± 0.005 0.001 D 0.022 ± 0.005 <0.001 D
The CPMG pulse sequence was used to emphasize the small metabolites in the plasma, while the BPP-LED pulse sequence presented only broad peaks from the macromolecules in samples. Data are presented as
mean ± SD, and U (up) and D (down) next to numbers indicates the significant elevated or reduced concentration of metabolites (P <0.05), respectively. AO = anovulation; FA = fatty acid; HA = hyperandrogenism;



















carbohydrate metabolic disorder in the patients with poly-
cystic ovaries.
However, a total of 45 plasma metabolites were identi-
fied as endogenous metabolites by GC/TOF-MS analysis,
including amino acids, fatty acids, sugars, and organic
acids. Multivariate statistical analysis was performed, and
the OSC-partial least squares (PLS) scores plot illustrated
that each PCOS phenotype exhibited obvious differences
with the control group (Figure 2). Moreover, there were
diverse significant differences were noted in the plasma
levels of each PCOS phenotypes compared with the con-
trol group. The productions of lactate and long-chain fatty
acids (for example, linoleic acid, palmic acid and stearic
acid) were induced, whereas the production of glucose
was inhibited in PCOS groups, which was consistent with
1H NMR data (Table 3).
Metabolic disturbance of amino acids in PCOS
Amino acids play important roles both as basic substrates
and as regulators in many metabolic pathways. Interest-
ingly, marked change in the plasma amino acid pattern
was detected by GC/TOF-MS analysis in each PCOS phe-
notype comparing to the control, suggesting the abnorm-
ality of amino acids catabolism and biosynthesis (Table 3).
We observed that the concentrations of valine and tryoto-
phan were generally elevated in PCOS groups. By contrast,
the levels of glycine and proline in four phenotypes of
PCOS were decreased significantly compared with the cor-
responding control group levels. Additionally, higher levels
of alanine, serine, threonine, phenylalanine, ornithine and
tyrosine were observed in anovulatory PCOS patients.
Surprisingly, plasma serine and threonine levels were
inhibited in women with PCOS with normal ovulation as
compared with controls. Moreover, the concentrations of
total endogenous amino acids and gluconeogenic amino
acids were markedly increased in the classic and nonhy-
perandronetic PCOS phenotypes (A and B groups) com-
pared to the control samples, indicating the induced
proteolysis and inhibited gluconeogenesis in these women
with PCOS. In particular, although both BACC and AAA
concentrations were augmented in PCOS samples, the
ratio of BCAA to AAA was dramatically reduced in ano-
vulatory PCOS phenotypes as compared with the control
group, respectively.
Effects of obesity and insulin resistance on the metabolic
changes in PCOS
Approximately 40% patients with PCOS in our study
were obese (BMI ≥25) and 30% were suffered from insu-
lin resistance (Homeostasis Model Assessment of Insulin
resistance (HOMA-IR) ≥2.69) [18]. To evaluate the
potential interferences of obesity and insulin resistance
with the metabolic abnormalities in PCOS, we performed
the correlation analysis to test the associations between
specific metabolites and PCOS, BMI and IR. Taken
together, we observed the significantly positive associa-
tion of linoleic acid, stearic acid, alanine, serine and tryp-
tophan concentrations with the occurrence of PCOS
disease, and the obviously negative relations of glucose,
proline and isoleucine levels with PCOS controlling for
age, BMI and IR (Additional file 1). However, plasma
concentrations of valine, glycine, serine and threonine
Figure 2 Gas chromatography/time-of-flight mass spectrometry (GC/TOF-MS) analysis. Orthogonal signal correction/partial least squares
(OSC-PLS) scores plot of GC/TOF-MS data of plasma from the four phenotypes of polycystic ovary syndrome (PCOS) patients (red squares) and
the controls (black triangles). (A) PCOS patients with hyperandrogenism (HA), anovulation (AO) and polycystic ovaries (PCO) (HA+AO+PCO) vs
controls; (B) PCOS patients (AO+PCO) vs controls; (C) PCOS patients (HA+AO) vs controls; (D) PCOS patients (HA+PCO) vs controls.
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Table 3 Changes in the relative levels of metabolites detected by gas chromatography/time-of-flight mass spectrometry (GC/TOF-MS) in the plasma of
polycystic ovary syndrome (PCOS) and control subjects
Retention time, min Identified metabolites Control group A group (HA+AO+PCO) B group (AO+PCO) C group (AO+HA) D group (HA+PCO)
Mean ± SD P adjusted Mean ± SD P adjusted Mean ± SD P adjusted Mean ± SD P adjusted
6.249 Lactate 2.17 ± 0.27 2.29 ± 0.46 0.039 U 2.5 ± 0.54 0.026 U 2.03 ± 0.61 0.079 - 2.82 ± 0.77 0.035 U
25.818 Glucose 4.96 ± 0.78 4.03 ± 0.32 0.019 D 4.02 ± 0.41 0.034 D 4.29 ± 0.62 0.054 - 4.27 ± 0.78 0.04 D
26.184 Galactose 1.94 ± 0.29 1.76 ± 0.13 0.582 - 1.69 ± 0.13 0.45 - 1.87 ± 0.43 1.000 - 1.87 ± 0.4 1.000 -
28.818 Palmic acid 0.72 ± 0.12 0.76 ± 0.12 0.876 - 0.91 ± 0.11 0.001 U 0.95 ± 0.15 <0.001 U 0.82 ± 0.13 0.014 U
29.751 Uric acid 0.27 ± 0.13 0.58 ± 0.17 <0.001 U 0.30 ± 0.21 1.000 - 0.16 ± 0.15 0.088 - 0.31 ± 0.18 1.000 -
31.785 Linoleic acid 0.05 ± 0.03 0.1 ± 0.09 0.003 U 0.36 ± 0.18 0.001 U 0.5 ± 0.21 <0.001 U 0.15 ± 0.16 0.019 U
32.418 Stearic acid 0.85 ± 0.14 0.91 ± 0.08 0.17 - 0.98 ± 0.08 0.023 U 0.96 ± 0.12 0.067 U 0.94 ± 0.10 0.01 U
45.636 Cholesterol 0.72 ± 0.35 0.69 ± 0.33 0.043 D 0.68 ± 0.26 0.038 D 0.80 ± 0.34 0.805 - 0.96 ± 0.73 0.342 -
7.149 Alanine 0.43 ± 0.14 0.56 ± 0.1 <0.001 U 0.63 ± 0.11 0.001 U 0.61 ± 0.6 <0.001 U 0.48 ± 0.17 0.813 -
9.866 Valine 0.46 ± 0.07 0.52 ± 0.1 <0.001 U 0.57 ± 0.07 0.001 U 0.53 ± 0.11 0.001 U 0.5 ± 0.08 0.042 U
11.3 Leucine 0.28 ± 0.09 0.28 ± 0.06 1.000 - 0.29 ± 0.09 1.000 - 0.32 ± 0.07 0.399 - 0.37 ± 0.11 0.002 U
11.85 Isoleucine 0.19 ± 0.08 0.18 ± 0.06 0.195 - 0.19 ± 0.05 1.000 - 0.18 ± 0.07 1.000 - 0.12 ± 0.05 0.001 D
11.933 Proline 0.59 ± 0.07 0.28 ± 0.08 <0.001 D 0.25 ± 0.08 0.001 D 0.26 ± 0.08 0.001 D 0.19 ± 0.07 0.001 D
12.15 Glycine 0.59 ± 0.09 0.49 ± 0.08 0.004 D 0.53 ± 0.08 0.026 D 0.50 ± 0.09 0.008 D 0.47 ± 0.11 0.001 D
13.6 Serine 0.29 ± 0.08 0.38 ± 0.07 <0.001 U 0.38 ± 0.07 <0.001 U 0.35 ± 0.09 0.012 U 0.24 ± 0.08 0.015 D
14.233 Threonine 0.35 ± 0.11 0.42 ± 0.08 <0.001 U 0.42 ± 0.08 0.001 U 0.39 ± 0.1 0.085 U 0.27 ± 0.09 0.006 D
16.317 Aspartate 0.13 ± 0.09 0.13 ± 0.09 1.000 - 0.2 ± 0.14 0.005 U 0.12 ± 0.06 1.000 - 0.08 ± 0.07 1.000 -
19.867 Phenylalanine 0.10 ± 0.05 0.24 ± 0.08 <0.001 U 0.21 ± 0.08 0.001 U 0.19 ± 0.08 0.001 U 0.11 ± 0.05 1.000 -
24.118 Ornithine 0.13 ± 0.08 0.25 ± 0.09 <0.001 U 0.23 ± 0.09 0.001 U 0.2 ± 0.1 0.002 U 0.12 ± 0.08 1.000 -
26.334 Lysine 0.28 ± 0.9 0.5 ± 0.18 <0.001 U 0.39 ± 0.11 0.126 - 0.34 ± 0.10 1.000 - 0.33 ± 0.26 1.000 -
26.634 Tyrosine 0.09 ± 0.04 0.24 ± 0.06 0.001 U 0.2 ± 0.07 0.001 U 0.17 ± 0.07 0.036 U 0.14 ± 0.07 1.000 -
31.7 Tryptophan 0.02 ± 0.01 0.17 ± 0.04 0.001 U 0.09 ± 0.06 0.003 U 0.05 ± 0.04 0.03 U 0.06 ± 0.05 0.002 U
Endogenous AAs 3.8 ± 0.71 4.37 ± 0.62 0.001 U 4.32 ± 0.64 0.001 U 4.0 ± 0.73 0.294 - 3.38 ± 0.78 0.153 -
Gluconeogenic AAs 3.4 ± 0.62 3.93 ± 0.52 0.003 U 4.14 ± 0.67 <0.001 U 3.6 ± 0.70 1.000 - 2.92 ± 0.65 0.002 D
BCAA 0.87 ± 0.2 0.95 ± 0.22 1.000 - 1.03 ± 0.17 0.024 U 1.04 ± 0.20 0.017 U 0.98 ± 0.17 0.865 -
AAA 0.21 ± 0.1 0.66 ± 0.17 0.001 U 0.49 ± 0.17 0.001 U 0.4 ± 0.16 0.019 U 0.31 ± 0.17 1.000 -
BCAA/AAA 4.82 ± 1.8 1.51 ± 0.37 <0.001 D 2.35 ± 0.91 <0.001 D 3.09 ± 1.62 0.002 D 4.3 ± 2.50 0.298 -
Data are presented as mean ± SD, and U (up) and D (down) next to numbers indicates the significant elevated or reduced concentration of metabolites (P <0.05). Endogenous amino acids include all amino acids
except for ornithine; gluconeogenic amino acids include alanine, valine, isoleucine, proline, glycine, serine, threonine, aspartate, phenylalanine, lysine and tyrosine; branched-chain amino acids (BCAA) include leucine,


















were closely correlated with IR and obesity (Additional
file 2). Additionally, significant positive association of lac-
tate and leucine concentrations with IR was observed
independently of obesity. Extraordinarily, significant
decreases of serine and threonine levels were observed in
both obese women with PCOS and patients with IR com-
paring to the nonobese PCOS subjects and patients with
normal insulin sensitivity, respectively. In contrast, serine
and threonine concentrations in PCOS samples were
notably enhanced as compared with the normal controls
independently of obesity or IR, indicating opposite
impacts of PCOS and its two common features on the
metabolism of serine and threonine (Additional files 3
and 4).
Metabolic pathways associated with PCOS
With the aid of the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database, metabolic pathways asso-
ciated with PCOS were summarized in Figure 3 based
on the changes of intermediates concentrations detected
in this study. The affected metabolic pathways in PCOS
patients included the tricarboxylic acid (TCA), glycoly-
sis, ketogenesis, lipolysis, proteolysis and urea cycles.
Elevated rates of peripheral glucose uptake and dimin-
ished hepatic lactate conversion to glucose suggested
the enhanced glycolysis in muscle and inhibited gluco-
neogenesis in liver during occurrence of PCOS. Addi-
tionally, the PCOS patients were accompanied by
marked impairment of TCA cycle. This was reflected in
the reduced citrate level and elevated levels of plasma
threonine, valine, phenylalanine and tyrosine, inducing a
drop in succinyl-CoA and fumarate. In addition, the
women with PCOS advanced quickly to a state of lipoly-
sis and protein catabolism, evidenced by increased levels
of plasma fatty acids and amino acids. An elevated level
of ornithine and decreased level of arginine implied the
imbalance of urea cycle (a reduced level of citrate and
arginine has been reported [19]).
Discussion
The etiology of PCOS is complex, and the present results
demonstrated the changes of metabolite profiles in the
different PCOS phenotypes, which reflected the meta-
bolic heterogeneity of the PCOS population and offered
potential to study the underlying causes. Our findings
clearly show that PCOS is associated with aberrations in
Figure 3 Metabolic pathways associated with polycystic ovary syndrome (PCOS) development. The schematic map was modified from
[17], with permission from the American Chemical Society (copyright (2007)). Amino acid metabolic pathways are grouped according to their
points of entry into the tricarboxylic acid (TCA) cycle, glycolysis, ketogenesis, lipolysis, proteolysis and urea cycles. Glucogenic amino acids can be
broken down into one of the following metabolites: pyruvate (Ala, Ser, Thr, Try, Gly, Cys), a-ketoglutarate (KGA) (Pro, Arg, His, Glu, Orn, Cit),
succinyl CoA (Val, Thr, Ile, Met), fumarate (Phe, Tyr) or oxaloacetate (OAA) (Asp); while ketogenic amino acids can be broken down into
acetoacetyl-CoA (Phe, Tyr, Trp, Lys, Leu) or acetyl-CoA (Ile, Leu, Try). The increase (red) and decrease (blue) of metabolites concentrations in the
PCOS plasma were on the basis of both our data and previous report (reduction of arginine and citrate in PCOS patients [19]). The glycolysis,
lipolysis and proteolysis pathways were induced in women with PCOS, whereas the TCA cycle and ketogenesis were inhibited in PCOS. Fatty
acids included linoleic acid, palmic acid and stearic acid. Amino acids are abbreviated using the standard three-letter convention. AA = amino
acids; ACAC-CoA = acetoacetyl-CoA; ASA = argininosuccinate.
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carbohydrate metabolism. The significant elevation of
lactate and glucogenic amino acids and the reduction of
glucose in PCOS plasma implied elevated glycolysis in
muscle and decreased gluconeogenesis in liver during
PCOS pathogenesis. The strongly positive correlation of
lactate level to insulin resistance further suggested insulin
stimulated glucose uptake and consumption in the mus-
cle of these PCOS patients (Additional files 1 and 4).
In terms of lipid metabolism, subjects with PCOS had
higher triglycerides, LDL and VLDL levels and a lower HDL
level (Tables 1 and 2), which is consistent with previous
reports [20,21] and manifested lipid disorders and dyslipide-
mia development. Moreover, plasma metabolic profiles in
our results indicated the dramatically increased levels of
three long-chain fatty acids (palmic acid, stearic acid, lino-
leic acid) in PCOS samples compared with the controls,
irrespective of obesity or insulin resistance (Table 3 and
Additional file 1). Previous reports have suggested the levels
of linoleic acid in the follicular fluid significantly decreased
during follicle size increase in cattle, and linoleic acid sup-
plementation could inhibit bovine cumulus expansion, lead-
ing to reduce oocyte maturation and developmental
potential [22]. The increase of linoleic acid levels in PCOS
plasma may be accompanied by a similar change in the folli-
cular fluid, thus resulting in blocked oocyte maturation and
ovulation in PCOS. Additionally, linoleic acid displayed
potent proinflammatory activities [23], so the higher level of
linoleic acid might be not only linked with increased lipoly-
sis and ovarian dysfunction, but also to the chronic low-
grade inflammation in PCOS patients.
Additionally, our study showed different amino acid pro-
files in PCOS phenotypes for the first time, and the dis-
tinct patterns of free amino acids in PCOS and control
subjects in the current study provided us important bio-
chemical information and metabolic signatures that
enabled the diagnosis of PCOS. More recently, some pro-
spective studies have reported potential amino acid bio-
markers for IR and diabetes. Newgard et al. [24] reported
that circulating concentrations of branched-chain amino
acids (Val, Leu, Ile) contributed to development of obe-
sity-associated insulin resistance. Wang et al. [25] identi-
fied 5 branched-chain and aromatic amino acids (Val, Leu,
Ile, Phe, Tyr) from 61 metabolites profiled as the markers
of insulin resistance and predictors of the future develop-
ment of DM2. Further, Wurtz et al. [26] reported the
alterations in branched-chain and aromatic amino acid
metabolism precede hyperglycemia in the general popula-
tion. In our study, glycine was a novel amino acid we
found which was closely related to IR except for valine
and leucine, (Additional file 2). Elevated level of valine and
reduced level of glycine were also observed in the women
with PCOS without insulin resistance as compared with
controls, and these changes were further aggravated when
the patients had impaired insulin sensitivity (Additional
file 4), which underlined valine and glycine were associated
with other metabolic disturbances except for IR in the
development of PCOS. Additionally, glycine has been
shown to improve the proinflammatory profile and upre-
gulate adiponectin gene expression in vitro [27]. Adipo-
nectin levels seem to be lower in women with PCOS
compared with non-PCOS controls after controlling for
BMI-related effects [28]. Consequently, the reduced level
of glycine might downregulate the expression of adiponec-
tin and lead to the inflammation in women with PCOS
independently of obesity. Thus, glycine could also be use-
ful as a modulator of the inflammatory state observed in
PCOS.
Leucine has been shown to rescue insulin signaling via
activation of the mTOR pathway, and increasing dietary
leucine intake can improve insulin sensitivity and restore
many metabolic abnormalities [29,30]. Leucine uptake gra-
dually increases during follicle development, whereas this
increasing rate decreases in preovulatory follicles [31].
Considering there was no significant difference of leucine
level between women with PCOS with normal insulin sen-
sitivity and control subjects in our results, we speculated
that alterations of leucine plasma level in PCOS patients
with IR might be entirely due to the impairment of insulin
signaling. In terms of aromatic amino acids, the obvious
changes of AAA levels and BCAA/AAA ratio were inde-
pendent of insulin resistance and obesity, which were
inconsistent with other findings in DM2 [25,26]. Although
IR is a common manifestation of PCOS and women with
PCOS have an increased risk of developing DM2, the
pathogenesis of PCOS and DM2 were entirely different,
which was indicated by these distinct amino acid profiles
in women with the two diseases.
Some previous reports have shown the clinical and
endocrine disorders in different PCOS phenotypes [32,33].
In this study, the classic phenotype of PCOS was asso-
ciated with more adverse biochemical and metabolic
changes than other phenotypes when compared with con-
trols. Alterations of LH level, LH/FSH ratio, AAA levels
and BCAA/AAA ratio were much more severe in classic
PCOS than in other PCOS phenotypes (Tables 1 and 3).
Moreover, ovulatory PCOS phenotype had different
changes of metabolic profile than the anovulatory PCOS
phenotypes. The total concentration of endogenous
amino acids was suppressed in ovulatory women with
PCOS compared with the control group (Table 3), which
demonstrated increased protein synthesis in those
patients as Carmina et al. had reported that lean muscle
mass was increased in women with PCOS [34]. However,
the total level of endogenous amino acids was elevated in
PCOS patients accompanied with the clinical feature of
polycystic ovary and anovulation, indicating elevated pro-
tein degradation during ovarian dysfunction. We further
noted ovulatory dysfunction of PCOS patients with raised
Zhao et al. BMC Medicine 2012, 10:153
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production of the following amino acids: serine, threo-
nine, phenylalanine, tyrosine and ornithine were signifi-
cantly elevated only in the anovulatory PCOS subgroups,
which implied that enhancements of these five amino
acids might be directly related to ovulatory dysfunction
by their increased ovarian uptake in PCOS patients. The
main pathway to de novo biosynthesis of serine starts
with the glycolytic intermediate 3-phosphoglycerate, so
the increase of serine in anovulatory PCOS patients prob-
ably arises from increased glycolysis. Specially, the levels
of serine and threonine were obviously reduced in ovula-
tory PCOS subtype, which might be due to the signifi-
cantly negative correlations of serine and threonine to
obesity and insulin resistance (Additional files 3 and 4).
The concentrations of these two amino acids were indeed
inhibited in PCOS patients with obesity or insulin resis-
tance as compared with PCOS controls, respectively
(Additional files 1 and 2). All of these findings together
confirmed the metabolic heterogeneity of PCOS due to
various clinical features. In addition, the elevated aro-
matic amino acids levels and decreased BCAA/AAA ratio
in anovulatory patients were strongly related to the sever-
ity of the PCOS phenotypes (Table 3). In relation to this
point, the significantly decreased BCAA/AAA ratio may
be considered as a crucial marker of the development of
PCOS.
Furthermore, androgen excess was the most common
phenotype of PCOS and was somehow associated with
insulin resistance. However, we observed different roles of
these two phenotypes on metabolic components of PCOS.
Androgen excess was closely related to the lipid metabolic
disorder, the levels of three long-chain fatty acids (for
example, palmic acid, stearic acid, linoleic acid) were all
significantly reduced in PCOS patients with hyperandro-
genism compared with women with PCOS without clinical
or biochemical hyperandrogenism (Additional file 5),
whereas no significant difference of these fatty acids levels
were observed between PCOS cases with IR and without
IR. Additionally, lactate, leucine and glycine were closely
related to insulin resistance of PCOS, but the levels of
these metabolic components were not influenced by
androgen excess of PCOS (Additional files 4 and 5).
Otherwise, our results of metabolic signature in PCOS
are partially inconsistent with previous reports. Escobar-
Morreale et al. found PCOS was associated with decreased
alanine concentrations [35], but GC/TOF-MS analysis in
our data revealed obviously elevated levels of alanine in
PCOS plasma. Alanine is transferred to the circulation
mainly by skeletal muscle. There are two main pathways
of alanine production: directly from protein degradation,
and via the transamination of pyruvate by alanine amino-
transferase (ALT). Women with PCOS have been impli-
cated to have higher levels of ALT in the serum [36],
which could accelerate the transamination of pyruvate to
alanine. Additionally, increased expression of pyruvate
dehydrogenase kinase 4 (PDK4) mRNA in PCOS patients
[37] can enhance the peripheral concentration of this
enzyme and subsequently promote the conversion of pyru-
vate to lactate, supporting the higher lactate concentration
and glycolytic rate in our results. In addition, all control
subjects have normal weight and insulin sensitivity, and
we need samples from control women with obesity or
insulin resistance for comparison to further analyze the
effect of obesity and insulin resistance on the metabolic
changes in PCOS. Another limitation is that we did not
perform the subsequent replication using more samples.
We are now enlarging our sample size to confirm these
findings and trying to make a possible diagnostic model
using the combined values of differentiate metabolites.
Conclusions
PCOS is a persisting challenge for clinical and basic
research to elucidate its origins and distinguish primary
pathological changes from secondary environmental dis-
ruptions. This study has important significance not only
in identifying novel metabolic biomarkers that predict
PCOS and its long-term complications, but also in bet-
ter understanding of the metabolic pathways directly
affected during PCOS occurrence, which may provide a
rational basis for the development of novel therapeutic
targets. Further correlation-based network analysis may
help us to generate a diagnostic index of PCOS based
on the plasma concentrations of amino acids and other
metabolites detected in this study.
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